Targeting B Cell Malignancies? Raji-Luc is a Model to Test CD19-Directed CAR-T Cells and Other Novel Approaches
Anti-tumor Activity of Anti-CD20 Monoclonal Antibody—Rituximab Similar to CD19, CD20 is also a marker of B cells and was an initial target of drugs focusing on B cell malignancies like Non-Hodgkin’s lymphoma. The clinical development of the anti-CD20 monoclonal antibody, rituximab, proved ground-breaking for use of monoclonal antibodies as oncology […]